Anemia Market is projected to reach USD 49.73 billion by 2034

The global Anemia Market was valued at USD 26.85 billion in 2024 and is projected to reach USD 49.73 billion by 2034, growing at a CAGR of 6.4% during the forecast period (2025-2034). The market is expanding due to rising global prevalence of anemia, increased screening for iron deficiency, growing burden of chronic diseases, and greater adoption of advanced anemia therapeutics across hospitals and specialty clinics.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71296

Anemia is one of the most widespread hematological disorders globally, affecting more than 1.9 billion people, particularly women of reproductive age, children, chronic kidney disease (CKD) patients, cancer patients, and the elderly. It is characterized by reduced hemoglobin levels, leading to fatigue, weakness, impaired concentration, shortness of breath, and reduced quality of life.

Therapeutic demand continues to grow as anemia is increasingly recognized as a serious public health challenge linked to nutritional deficiencies, chronic inflammation, parasitic infections, renal failure, and cancer therapies.

Key Market Highlights
• 2024 Market Size: USD 26.85 billion
• 2034 Forecast: USD 49.73 billion
• CAGR (2025-2034): 6.4%
• Largest Etiology Segment: Iron-deficiency anemia
• Fastest-Growing Segment: CKD-related anemia treated with ESAs & HIF-PHIs

Epidemiology & Patient Insights
1. Global Prevalence
• Affecting over 1.9 billion people, anemia remains one of the world's most common health conditions.
• Prevalence is highest in:
o Women (pregnancy-related anemia)
o Children (nutritional deficiencies)
o CKD & dialysis patients
o Cancer patients receiving chemotherapy
2. Types of Anemia Driving Market Demand
• Iron-deficiency anemia
• Anemia of chronic kidney disease
• Hemolytic anemia
• Aplastic anemia
• Megaloblastic anemia (B12 & folate deficiency)
• Anemia of chronic disease/inflammation
• Sickle cell disease-related anemia

Market Growth Drivers
1. Rising Burden of Iron Deficiency
Iron deficiency remains the leading cause of anemia worldwide, driven by poor diet, malabsorption, pregnancy, and heavy menstrual bleeding.
2. Increasing CKD & Dialysis Population
CKD-related anemia significantly increases demand for:
• Erythropoiesis-Stimulating Agents (ESAs)
• Intravenous (IV) iron formulations
• Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) - a major growth segment
3. Strong Adoption of Advanced Injectables
New IV iron therapies offer safer, faster iron repletion with fewer infusions.
4. Rising Cancer Incidence
Chemotherapy-induced anemia is a major contributor to ESA demand.
5. Public Health Initiatives
Many countries conduct:
• Iron and folate supplementation programs
• Maternal anemia screening
• School-based nutrition programs

Market Restraints
• ESA-related cardiovascular risk concerns
• Limited awareness in low-income countries
• High treatment cost for advanced therapies
• Misdiagnosis or underdiagnosis of anemia causes
• Safety concerns with frequent blood transfusions

Market Opportunities
1. Growth of HIF-PHI Drug Class
Oral HIF-PHIs represent a transformative new option for CKD anemia, supporting:
• Improved patient convenience
• Better regulatory approval momentum
• Growing physician acceptance
2. Development of Safer, Faster IV Iron Formulations
High-dose, single-infusion products are increasingly preferred.
3. Precision Hematology
Advanced diagnostics help identify root causes for optimized treatment.
4. Expansion in Emerging Markets
High disease burden + rapid healthcare modernization = major growth potential.
5. Combination Therapies
Supplementation + ESA + IV iron protocols improve outcomes in refractory anemia.

Segmentation Overview
By Type
• Iron deficiency anemia
• CKD-related anemia
• Aplastic anemia
• Hemolytic anemia
• Megaloblastic anemia
• Sickle cell anemia
• Chronic disease/inflammation anemia

By Treatment
• Oral iron supplements
• Intravenous iron formulations
• ESAs (erythropoietin, darbepoetin)
• HIF-PHIs (emerging)
• Vitamin B12 & folate therapies
• Blood transfusions

By Route of Administration
• Oral
• Intravenous
• Subcutaneous

By End User
• Hospitals
• Specialty clinics
• Hemodialysis centers
• Retail & online pharmacies

Explore Full Report here: https://exactitudeconsultancy.com/reports/71296/anemia-market

Regional Insights
North America - Largest Market
High CKD prevalence, strong ESA adoption, and advanced hematology infrastructure.
Europe - Robust Screening Programs
Large focus on maternal anemia, older adults, and chronic disease management.
Asia Pacific - Fastest Growing Market
Massive anemia burden, expanding government programs, and rising use of IV iron.
Latin America - Increasing Access
Improving diagnosis rates and health system modernization.
Middle East & Africa - High Untreated Prevalence
Large anemia burden, especially among women and children.

Competitive Landscape
Major players in the Anemia Market include:
• Amgen
• Vifor Pharma
• Daiichi Sankyo
• Pfizer
• GlaxoSmithKline
• Johnson & Johnson
• Akebia Therapeutics
• Astellas Pharma
• Sanofi
• Novartis
Focus areas: ESAs, HIF-PHIs, IV iron products, biosimilars, and supplementation therapies.

Recent Market Developments
• Expansion of HIF-PHI approvals in multiple regions
• Safer next-gen IV iron formulations entering commercial markets
• Enhanced clinical guidelines for anemia in CKD and oncology
• Increased use of biosimilar ESAs in emerging markets
• Growth of anemia management programs targeting pregnant women

Future Outlook (2025-2034)
The Anemia Market will continue to expand as:
• HIF-PHIs gain global acceptance
• IV iron products advance in safety and efficacy
• Personalized anemia management evolves
• Chronic diseases increase worldwide
• Governments scale national anemia-reduction programs
By 2034, the market is expected to reach USD 49.73 billion, driven by innovation, high disease prevalence, and improving access to hematology care.

This report is also available in the following languages : Japanese (貧血市場), Korean (빈혈 시장), Chinese (贫血市场), French (Marché de l'anémie), German (Anämie-Markt), and Italian (Mercato dell'anemia), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71296

Our More Reports:
Renal Anemia Market
https://exactitudeconsultancy.com/reports/71449/renal-anemia-market

Fanconi Anemia Market
https://exactitudeconsultancy.com/reports/71279/fanconi-anemia-market

Iron Deficiency Anemia Market
https://exactitudeconsultancy.com/reports/71286/iron-deficiency-anemia-market

Warm Autoimmune Hemolytic Anemia Market
https://exactitudeconsultancy.com/reports/71295/warm-autoimmune-hemolytic-anemia-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.